PAVM vs. LYRA, APYX, SEPA, NUVO, LNSR, DRIO, ICCM, LUCD, CTSO, and DXR
Should you be buying PAVmed stock or one of its competitors? The main competitors of PAVmed include Lyra Therapeutics (LYRA), Apyx Medical (APYX), SEP Acquisition (SEPA), Holdco Nuvo Group D.G (NUVO), LENSAR (LNSR), DarioHealth (DRIO), IceCure Medical (ICCM), Lucid Diagnostics (LUCD), Cytosorbents (CTSO), and Daxor (DXR). These companies are all part of the "surgical & medical instruments" industry.
PAVmed (NASDAQ:PAVM) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, community ranking, dividends and analyst recommendations.
Lyra Therapeutics has lower revenue, but higher earnings than PAVmed. Lyra Therapeutics is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lyra Therapeutics had 2 more articles in the media than PAVmed. MarketBeat recorded 4 mentions for Lyra Therapeutics and 2 mentions for PAVmed. PAVmed's average media sentiment score of 0.44 beat Lyra Therapeutics' score of 0.15 indicating that PAVmed is being referred to more favorably in the media.
PAVmed received 179 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 65.90% of users gave PAVmed an outperform vote while only 61.11% of users gave Lyra Therapeutics an outperform vote.
PAVmed presently has a consensus target price of $21.00, suggesting a potential upside of 1,237.58%. Lyra Therapeutics has a consensus target price of $7.13, suggesting a potential upside of 2,036.43%. Given Lyra Therapeutics' higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than PAVmed.
19.9% of PAVmed shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 12.6% of PAVmed shares are held by insiders. Comparatively, 17.4% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
PAVmed has a net margin of -2,037.67% compared to Lyra Therapeutics' net margin of -4,099.82%. PAVmed's return on equity of 0.00% beat Lyra Therapeutics' return on equity.
PAVmed has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.
Summary
PAVmed beats Lyra Therapeutics on 10 of the 19 factors compared between the two stocks.
Get PAVmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
